NEW YORK, Dec. 14, 2017 /PRNewswire-USNewswire/ -- Scientists have taken a significant step forward in efforts to harness
Montefiore holds the investigational new drug application from the FDA to test the safety and feasibility of the therapy. Working with the National Cancer Institute-designated Albert Einstein Cancer Center, the trial kicked off this summer.
The goal of the pilot study is to enroll five patients and confirm the feasibility, and safety of the therapy for solid tumors, such as breast cancer, sarcomas and lung cancer.
Eligibility for the trial requires highly specific criteria:
It's all about the blood, so NYBC plays a critical role:
"We isolate a person's blood cells and grow them in the lab with a virus that inserts new DNA into the blood cells," says Amanda Marchiando, PhD, MPH, Cellular Therapy & Regenerative Medicine Scientist at New York Blood Center. "This reprograms the cells to recognize the NY ESO-1 protein on a patient's tumors and attack it."
Once newly engineered cells are created in the NYBC, patients' bodies will be prepared for a cell transfusion. This will include one week of chemotherapy at Montefiore to wipe out many of the remaining white blood cells. The clean slate allows the new and improved cells, which are delivered through an IV-bag in 20 minutes, to become the first in line to attack the cancer. Immunotherapy is also given to make the re-engineered cells even stronger.
"We are optimistic that this therapy could become a viable option for people with cancer who are running out of options," says principal investigator Ira Braunschweig, M.D., director, Stem Cell Transplantation and clinical program director, Hematologic Malignancies, Montefiore Einstein Center for Cancer Care, Associate Professor, Department of Medicine, Einstein.
This scientific development builds off the research of Dr. Steven Rosenberg of the National Cancer Institute.
"Though the main goal of the phase one pilot study is making sure the treatment is safe, we always hope that our patients will be better than they were before they walked through our doors," says Katia Papalezova, M.D., surgical oncologist, Department of Surgery and director, Melanoma and Soft Tissue Tumors, co-director, IL-2 program, Montefiore Einstein Center for Cancer Care and Associate Professor of Surgery, Einstein, one of the lead clinical investigators. "It is gratifying to be on the frontlines of scientific research that has the potential to help so many people."
About Montefiore Health SystemMontefiore Health System is one of New York's premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children's Hospital at Montefiore, Burke Rehabilitation Hospital and close to 200 outpatient care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.
View original content:http://www.prnewswire.com/news-releases/patients-own-immune-cells-may-hold-the-key-to-fighting-deadly-cancers-300571088.html
SOURCE Montefiore Health System
Subscribe to our Free Newsletters!
Blood groups are of four important types determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All